We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert: Japan’s Sakigake Approval Pathway Aims to Cut Drug Lag
Expert: Japan’s Sakigake Approval Pathway Aims to Cut Drug Lag
Japanese regulators are hoping to halve drug review times and speed up patient access to novel therapies by encouraging companies to file NDAs first in Japan, or in tandem with U.S. and EU submissions, under an approval pathway approved in April.